HomeTrending StocksFulgent Genetics (FLGT) Stock Rocketed 34.46% In Extended Trading Following Strong Financial...

Fulgent Genetics (FLGT) Stock Rocketed 34.46% In Extended Trading Following Strong Financial Results

Shares of the testing services and comprehensive testing solutions technology company Fulgent Genetics, Inc. (NASDAQ: FLGT) rocketed 34.46% in the after-hour trades on Thursday. Release of the financial results helped the stock to rise in after-hour which remained declining in regular session.

Get the hottest stocks to trade every day before the market opens 100% ‎free. Click here now. 

What says the company’s performance?


3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free

Sponsored


Fulgent Genetics’ proprietary technology platform has helped it to build an extensive menu of tests, deliver accurate results, and optimize genetic reference panels, all at a fair price point. The Company combines Next Generation Sequencing (NGS) with its technology platform to perform full-genome sequencing together with deletion/duplication analysis in a variety of panel formats tailored to meet customer-specific needs. A new line of screening tests known as Picture Genetics launched in 2019. The tests were created by the Company to facilitate patient-based testing, providing a more personalized treatment approach.

Read More

As of March 2020, the Company has commercialized a variety of tests for the detection of SARS-CoV-2. These tests include NGS and reverse transcription-polymerase chain reaction (“RT-PCR”) based tests. These tests use upper respiratory specimens (nasal, nasopharyngeal, and oropharyngeal swabs) to detect SARS-CoV-2. The FDA has previously granted the Company Emergency Use Authorization (EUA) for RT-PCR-based tests and for the at-home testing service handled by Picture Genetics.

For the period ended December 31, 2020, FLGT today reported financial results for its Q4 and full-year 2020. Highlights of the financial results are as follows:

  • Revenue increased 3,400% from $8.4 million in the fourth quarter of 2019 to $295.0 million in the fourth quarter of 2020.
  • Income for the reported quarter was $166.3 million, or $6.16 per share against a loss of -$0.30 million or -$0.01 per share.
  • Adjusted EBITDA came at $230.1 million against that of $1.1 million in the same quarter a year ago.
  • A year-over-year increase of 1,200% was posted for 2020 total revenues of $421.7 million against revenue for 2019 of $32.5 million.
  • Full-year 2020 income was $214.3 million, or $8.91 per share compared to a loss of -$0.41 million or -$0.02 per share in 2019.

    Get the hottest stocks to trade every day before the market opens 100% ‎free. Click here now. 

  • Adjusted EBITDA for the year 2020 was $301.3 million against that of $4.9 million in 2019.

Get The Best Stocks To Trade Every Day!

Join now to get the NewsHeater.com pre-market morning brief 100% free

Must Read

Related News

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Get The Best Stocks To Trade Every Day!

Join now to get the NewsHeater.com pre-market morning brief 100% free

SPECIAL GIFT

WE HAVE A GIFT FOR YOU

Download Free eBook For

7 GROWTH STOCKS FOR 2021

100% free. stop anytime no spam